Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel + Itraconazole in CRPC
NCT02054793Phase 2Withdrawn
- Start
- Jun 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orteronel in castration-resistant prostate cancer (CRPC). Planned start Jun 2014; status: withdrawn.
02
Drugs
orteronel
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02054793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054793.